Picture of Open Access badges

Discover Open Access research at Strathprints

It's International Open Access Week, 24-30 October 2016. This year's theme is "Open in Action" and is all about taking meaningful steps towards opening up research and scholarship. The Strathprints institutional repository is a digital archive of University of Strathclyde research outputs. Explore recent world leading Open Access research content by University of Strathclyde researchers and see how Strathclyde researchers are committing to putting "Open in Action".


Image: h_pampel, CC-BY

Succinobucol-eluting stents increase neointimal thickening and peri-strut inflammation in a porcine coronary model

Watt, Jonathan and Kennedy, Simon and McCormick, Christopher and Agbani, Ejaife O and McPhaden, Allan and Mullen, Alexander and Czudaj, Peter and Behnisch, Boris and Wadsworth, Roger M and Oldroyd, Keith G (2013) Succinobucol-eluting stents increase neointimal thickening and peri-strut inflammation in a porcine coronary model. Catheterization and Cardiovascular Interventions, 81 (4). 698 - 708. ISSN 1522-1946

Full text not available in this repository. (Request a copy from the Strathclyde author)


The aim of this study was to assess the efficacy of stent-based delivery of succinobucol alone and in combination with rapamycin in a porcine coronary model. Current drugs and polymers used to coat coronary stents remain suboptimal in terms of long term efficacy and safety. Succinobucol is a novel derivative of probucol with improved antioxidant and anti-inflammatory properties. Polymer-free Yukon stents were coated with 1% succinobucol (SucES), 2% rapamycin (RES) or 1% succinobucol plus 2% rapamycin solutions (SucRES) and compared with a bare metal stent (BMS). RESULTS: The in vivo release profile of SucES indicated drug release up to 28 days (60% drug released at 7 days). 41 stents (BMS, n = 11; SucES, n =10; RES, n = 10; SucRES, n = 10) were implanted in the coronary arteries of 17 pigs. After 28 days, mean neointimal thickness was 0.31 ± 0.14 mm for BMS, 0.51 ± 0.14 mm for SucES, 0.19 ± 0.11 mm for RES and 0.36 ± 0.17 mm for SucRES (p <0.05 for SucES vs. BMS). SucES increased inflammation and fibrin deposition compared with BMS (p <0.05), whereas RES reduced inflammation compared with BMS (p <0.05). In this model, stent-based delivery of 1% succinobucol using a polymer-free stent platform increased neointimal formation and inflammation following coronary stenting.